Newswire (Published: Thursday, June 6, 2019, Received: Thursday, June 6, 2019, 7:19:19 PM CDT)

Word Count: 418

2019 JUN 06 (NewsRx) -- By a News Reporter-Staff News Editor at Cancer Gene Therapy Daily -- New research on Oncology - Prostate Cancer is the subject of a report. According to news reporting originating in London, Canada, by NewsRx journalists, research stated, “Early and accurate detection of cancer is essential to optimising patient outcomes. Of particular importance to prostate cancer is the ability to determine the aggressiveness of a primary tumour, which allows for effective management of patient care.”

Financial support for this research came from Prostate Cancer Canada.

The news reporters obtained a quote from the research from the University of Western Ontario, “In this work, we propose using gene vectors called tumour-activatable minicircles which deliver an exogenously encoded reporter gene into cancer cells, forcing them to produce a unique and sensitive biomarker. These minicircles express a blood reporter protein called secreted embryonic alkaline phosphatase mediated by the tumour-specific survivin promoter, which exhibits activity graded to prostate cancer aggressiveness. Together, these components underlie a detection system where levels of blood reporter are indicative of not only the presence, but also the metastatic potential of a tumour. Our goal was to assess the ability of tumour-activatable minicircles to detect and characterise primary prostate lesions. Our minicircles produced reporter levels related to survivin expression across a range of prostate cancer cell lines. When survivin-driven minicircles were administered intratumourally into mice, reporter levels in blood samples were significantly higher (p <0.05) in mice carrying prostate tumours of high versus low-aggressiveness.”

According to the news reporters, the research concluded: “Continued development of this gene-based system could provide clinicians with a powerful tool to evaluate prostate cancer aggressiveness using a sensitive and affordable blood assay.”

For more information on this research see: A novel approach for assessment of prostate cancer aggressiveness using survivin-driven tumour-activatable minicircles. Gene Therapy, 2019;26(5):177-186. (Nature Publishing Group - http://www.nature.com/; Gene Therapy - http://www.nature.com/gt/)

Our news correspondents report that additional information may be obtained by contacting J.A. Ronald, Robarts Research Institute-Imaging Laboratories, University of Western Ontario, London, ON, Canada, . Additional authors for this research include Y. Chen and J.A Ronald.

The direct object identifier (DOI) for that additional information is: https://doi.org/10.1038/s41434-019-0067-6. This DOI is a link to an online electronic document that is either free or for purchase, and can be your direct source for a journal article and its citation.

(Our reports deliver fact-based news of research and discoveries from around the world.)

Companies

The University of Western Ontario

Places

North America
Canada
Americas
Ontario
London

Subjects

Science and Technology
      Scientific Research
            Medical Research
                  Clinical Outcomes
Health and Wellness
      Medical Conditions and Diseases
            Cancer
                  Prostate Cancer
            Men's Health Issues
                  Prostate Cancer
      Health Sciences
            Medical Research
                  Clinical Outcomes
      Treatments and Therapies
            Gene and Genetic Therapy